Sanofi: Number of Employees 2010-2024 | SNY
Interactive chart of Sanofi (SNY) annual worldwide employee count from 2010 to 2024.
- Sanofi total number of employees in 2024 was 82,878, a 3.73% decline from 2023.
- Sanofi total number of employees in 2023 was 86,088, a 5.99% decline from 2022.
- Sanofi total number of employees in 2022 was 91,573, a 4.05% decline from 2021.
- Sanofi total number of employees in 2021 was 95,442, a 3.99% decline from 2020.
| Sanofi Annual Employee Count |
| 2024 |
82,878 |
| 2023 |
86,088 |
| 2022 |
91,573 |
| 2021 |
95,442 |
| 2020 |
99,412 |
| 2019 |
100,409 |
| 2018 |
104,226 |
| 2017 |
106,566 |
| 2016 |
106,859 |
| 2015 |
115,631 |
| 2014 |
113,496 |
| 2013 |
112,128 |
| 2012 |
111,974 |
| 2011 |
113,719 |
| 2010 |
101,575 |
| 2009 |
104,867 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$136.409B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
